Information about actively enrolling, ongoing, and completed clinical trials of cancer prevention, early detection, and supportive care, including phase I, II, and III agent and action trials and clinical trials management.
I was the first patient who Dr. Abraham enrolled on the NSABP B-31 clinical trial (chemo vs chemo + Trastuzumab in HER-2 positive breast cancer). I am grateful to him for presenting me with the opportunity to join the study 20 years ago in March 2001 and that I had the courage to participate, as I continue to do well to this day. This clinical trial ended up changing the landscape of treatment for future patients with breast cancer.
Type(s) of Trial: Treatment
Trial Link(s): Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
Monograph on Engaging Older Adults in Clinical Trials
A JNCI monograph on Engaging Older Adults in Cancer Clinical Trials Conducted in the National Cancer Institute Clinical Trials Network. The articles, developed through working groups formed for an NCI workshop held in April 2021 to address this issue, provide recommendations and new and innovative solutions to common barriers to accrual.
Researchers Search the Genome for Clues to Early Age Onset Cancers in Racial/Ethnic Minorities
While researchers have identified some of the genetic changes that lead to cancer development, a key knowledge gap remains: finding the genetic changes that drive the development of cancers that arise at an earlier age than average (early onset) in racially and ethnically diverse populations.
New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development
The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85 across the United States.